PREOPERATIVE SIMULTANEOUS CISPLATIN-BASED OR CARBOPLATIN-BASED CHEMOTHERAPY AND RADIOTHERAPY FOR SQUAMOUS-CELL CARCINOMA OF THE ORAL CAVITY

Citation
T. Kirita et al., PREOPERATIVE SIMULTANEOUS CISPLATIN-BASED OR CARBOPLATIN-BASED CHEMOTHERAPY AND RADIOTHERAPY FOR SQUAMOUS-CELL CARCINOMA OF THE ORAL CAVITY, Journal of surgical oncology, 63(4), 1996, pp. 240-248
Citations number
31
Categorie Soggetti
Surgery,Oncology
ISSN journal
00224790
Volume
63
Issue
4
Year of publication
1996
Pages
240 - 248
Database
ISI
SICI code
0022-4790(1996)63:4<240:PSCOCC>2.0.ZU;2-9
Abstract
Background: Encouraging results have been reported with cisplatin- or carboplatin-based chemotherapy regimens and simultaneous irradiation t reatment in advanced and unresectable head and neck head and neck canc er. We have therefore examined the effectiveness of such therapy on tu mor control, survival, and toxicity in patients with advanced oral squ amous cell carcinoma. Methods: Forty-one patients with squamous cell c arcinoma of the oral cavity (including soft palate) were treated preop eratively with cisplatin or carboplatin, and 5-fluorouracil or peplomy cin in combination with simultaneous irradiation to a target volume of 40Gy, and 2-6 weeks later, curative surgery was performed. Results: T hirty-eight patients (91.7%) had Stage III or IV disease, and three pa tients had Stage II lesions. The preoperative clinical responses of th e primary tumor were: 25 patients (61.0%) achieved a complete response (CR), 15 (36.6%) a partial response (PR), only 1 patient (2.4%) had s table disease or no change (NC). The overall response rate was 97.6%. Histological effects according to the grading system of Shimosato and coworkers [Jpn J Clin Oncol 1:19-35, 1971] were seen in 38/41 (92.7%). Of clinical CR patients, 73.9% were also histologic negative for tumo r. Side effects of this therapy were relatively low and reversible. Wi th a median follow-up of 52.8 months (range 17-92 months), 5-year cumu lative survival rates were 81.5% for all patients, 100% for Stage II, 88.6% for Stage III, and 76.4% for Stage IV patients, respectively. Th ere was no significant postoperative morbidity. Conclusions: This preo perative chemoradiotherapy regimen was highly active, well tolerated, and appeared to have a survival benefit even for advanced carcinomas o f the oral cavity. (C) 1996 Wiley-Liss, Inc.